Status:
NOT_YET_RECRUITING
A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients
Lead Sponsor:
SciNeuro
Conditions:
Diabetic Macular Edema
DME
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The objective of this study is to assess the safety, efficacy, and tolerability of SNP318 in patients with DME.
Detailed Description
DME is a prevalent complication of diabetic retinopathy, resulting in fluid accumulation in the macula due to the leakage of fluid from damaged retinal blood vessels. It is a leading cause of vision i...
Eligibility Criteria
Inclusion
- Main
- Confirmed diabetes mellitus Type 1 or Type 2, with stable glycemic control
- Center-involved DME with CST \>=320 µm (Study eye)
- BCVA between 82 and 25 letters, inclusive (Study eye)
- BCVA score ≥ 25 letters (Non-study eye)
- Main
Exclusion
- 1\. Use of the last intravitreal anti-VEGF injection in the study eye within 90 days prior to Screening
Key Trial Info
Start Date :
November 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT07199777
Start Date
November 1 2025
End Date
March 1 2027
Last Update
September 30 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.